Introduction
While little demonstrable difference exists between antidepressants in terms of efficacy,' toxicity in overdose varies widely.' We compared the fatal toxicities of antidepressants currently available in Britain individually and by group during 1987-92, during which time the selective serotonin reuptake inhibitors were introduced.
Methods
Antidepressants were assigned to four classes: monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors, and the so called "atypical"3 antidepressants. We obtained numbers of deaths in England, Wales, and Scotland due to acute poisoning by a single antidepressant. 4 ' The statistics and research division of the Department of Health supplied data on the number of antidepressant prescriptions for general medical practices within the NHS for England, Wales, and Scotland for 1987-9 and for England for 1990-2; for 1990-2 the Scottish data were provided by the Scottish Office Home and Health Department and the Welsh data by the Welsh Health Common Services Authority. Private general practice and most hospitals were excluded; figures for 1991 and 1992 include dispensing practices. About three quarters of all drug prescriptions are written by general practitioners. 6 7 Most patients with psychiatric disorders, however, are treated by general practitioners rather than by psychiatristsS" (90% to 98% of depressed patients"`). The exclusion of hospital prescriptions from our analysis should not, therefore, appreciably affect the outcome ofthis study.
We calculated the number of deaths per million prescriptions during the six years for all the drugs taken together; for each of the four groups of antidepressants; and for each drug individually. The X2 test was applied to the groups of antidepressants. The expected numbers of deaths are given for the individual drugs, with Fisher's exact test (one tailed) applied to the data. Confidence limits are calculated as x± 196 SD(x).
Using the prescribed data, we considered each preparation of each drug analysed, multiplied the strength of the preparation by the quantity prescribed, and divided this by the defined daily dose values (obtained from the World Health Organisation)." '3 We calculated the number of defined daily doses per prescription for each drug and the number of deaths per million defined daily doses prescribed.
Results
The mean annual number of deaths due to overdose with a single antidepressant over the six years was 268 (range 238 to 288). The Overdose with more than one substance, including antidepressants 424 24 BMJ VOLUME 310 28jANuARY 1995 had a significantly higher number of deaths per million prescriptions than expected compared with all the antidepressants taken together (P < 000 1). The monoamine oxidase inhibitors as a group had a lower than expected number of deaths per million prescriptions (P < 000 1). drugs (mianserin and trazodone) had a significantly lower number of deaths per million prescriptions. Three of the selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, and paroxetine) had a lower number of deaths per million prescriptions. No deaths were recorded for five drugs, all of which had low prescription figures (table III) . Calculation of data with defined daily doses showed a pattern that was broadly similar to the data derived from deaths per million prescriptions.
Discussion
The atypical antidepressants form a heterogeneous group of drugs, while the other antidepressants fall into three pharmacologically homogeneous groups. The selective serotonin reuptake inhibitors share a common mechanism of action, despite their remarkably differing chemical structures (fluvoxamine is a monocyclic agent, fluoxetine a bicyclic agent, sertraline a naphthylamine derivative, and paroxetine a phenyl piperidine derivative). They also had the lowest toxicity in overdose of the groups of drugs studied here. This accords with clinical experience.'"'7 The numbers of deaths per million prescriptions of antidepressants have been shown to be inversely related to their serotonin reuptake inhibition activity,'8 but this relation may be coincidental with their structural properties.
Shortcomings of a study of this nature include systematic error in prescription or mortality data, or both; confounding by prescriber biases or patient biases-such as, an inability to distinguish between the use of "first line" and "second line" drugs-or both biases; and the fact that no allowance was made for prescribing for indications other than those of concern to the study. These factors, however, are unlikely to affect the conclusions of our study as most biases run in favour of the tricyclic drugs, which are more widely used as first line drugs.'9 It is also possible that selective serotonin reuptake inhibitors are being prescribed to patients at greater risk of overdose.20 These drugs may also have a different role from tricyclic drugs in patients with depression resistant to treatment-for example, paroxetine3-or with suicidal thoughts-for example, fluoxetine ' and fluvoxamine.55 Our data thus provide a useful guide to the relative toxicities of drugs and an indication of the needs of prescribing policy and correlate with the results of median lethal dose in animals.23 Our data also agree with alternative indices based on deaths per million standard quantity units or deaths per thousand kilograms of drug prescribed. 24 The use of data on defined daily dose is gaining popularity internationally, mainly because defined daily doses provide a standardised technical measure of drug use that is not influenced by strength of dosage form. The dose is an assumed average daily dose for the main indication of a drug as determined by the Nordic Council on Medicines,'3 and this causes problems in its use in a study like ours. Problems include variation in the number of prescriptions that depressed patients have each year; discontinuation or non-compliance, especially for tricyclic drugs,25 which increases the apparent market share of other antidepressants; and prescription of drugs at doses below or above the defined daily dose. These factors might be expected to bias toxicity data in favour of the tricyclic drugs,26 but our analysis shows a strong correlation in the ranking of the two indices.
The differing toxicities of antidepressants in overdose should be considered against the wider issue of costs. The selective serotonin reuptake inhibitors are relatively expensive and are generally prescribed at effective daily doses, which can hardly be reduced to save on costs. Ironically, it is the cheaper, tricyclic 
in terms of safety and tolerability when given in an effective dose.34 Low toxicity in overdose is an important consideration in the drug treatment of depressed patients. Although it can be argued that a failed suicide attempt may only delay the ultimate outcome, it is widely accepted that a suicide attempt is a poor predictor of further attempts35; about 10% of those who fail to kill themselves with acute overdose go on to successful suicide." Furthermore, a drug overdose might bring the patient under closer medical supervision and lead to a better outcome to the depressive episode. While the present study shows that fatal overdose is an important problem, untreated depression may be even more important. 26 As Results-297 invasive interval cancers were detected. The rate of detection of interval cancers expressed as a proportion of the underlying incidence was 31% in the first 12 months after screening, 52% between 12 and 24 months, and 82% between 24 and 36 months.
Conclusion-The incidence of interval cancers in the third year after breast screening approaches that which would have been expected in the absence of screening and suggests that the three year interval between screens is too long.
Introduction
Trials of mass screening show that there is potential for reducing mortality from breast cancer in women. '4 Preliminary results from the NHS breast screening programme have been considered satisfactory5 but no information has been reported on the incidence of interval cancers. The incidence of these cancers must be kept comparatively low if the screening programme is to be successful. 6 Definition of interval cancer-A woman was considered to have an interval cancer if there was histological confirmation of a primary breast cancer within three years of her last negative screening assessment. We included women presenting with symptoms while on early recall but excluded women presenting with in situ disease.
Identification of interval cancers-Interval cancers were identified by linking records held by the screening centres and the North West Regional Cancer Registry. The registry has been population based since 1962 and uses multiple sources of registration to ascertain all cancers occurring in residents of the North Western region. The name, date of birth, and screening history of all women screened after 1 April 1988 were down loaded from the breast screening centres' computer systems. Name and date of birth were used to computer match screened women with registrations of primary breast cancer diagnosed after the start of the screening programme. Positive matches were confirmed by using the woman's address. Women with screen detected cancers were excluded. For the remaining women the date of the last negative screen and the date of the histological diagnosis of cancer were compared and probable interval cancers identified. The screening records of these women were examined to verify that they were interval cancers. In order to minimise delay in cancer registration a policy to "fast track" breast cancer registrations was introduced. However, a few interval cancers that had been reported to the screening centres direct were not registered at the cancer registry but are included in the analysis. In all but three cases this was due to the inevitable delay before a cancer is registered.
Statistical methods-The rate of detection of interval
